I jinxed myself. That closing statement in my last posting about things quieting down on the beat: fuggedaboutit. Yesterday and today, "The New York Times" ran above-the-fold, front-page stories on Lilly's marketing of Zyprexa. It's the company's top-selling drug and its biggest profit-maker -- analysts estimate the schizophrenia/bipolar disorder drug is responsible for one-third to as much as one-half of the company's bottom line.
Turning a new page on a story buzzing around Wall Street this week--could the New York Times company go private? A BusinessWeek article says former AIG chief Hank Greenberg --who is linked to the rumors--is just looking for some attention. On this morning’s "Squawk Box" Carl Quintanilla spoke with Jon Fine--Media Columnist for BusinessWeek.